Dossier
clinicaltrials
trial early
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Key claim: High-dose ruxolitinib combined with busulfan as pre-transplant conditioning may reduce splenomegaly and improve allogeneic stem cell transplant success in myelofibrosis patients.
Abstract
To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.
Why this matters
Splenomegaly is a major obstacle to successful allogeneic stem cell transplantation in myelofibrosis, associated with graft failure and delayed engraftment. Using high-dose ruxolitinib integrated into the conditioning regimen rather than only as a pre-transplant bridge represents a pragmatic spleen-directed strategy at the intersection of symptom management and curative therapy.